RxDoctor Payments Data

Caitlin Morgan

Family · Quantico, VANPI 1689219214

Payments from drug & device makers

$2,971in general payments, 2019–2025

Across 89 payments — averaging $33.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Boston Scientific$287
  • Amgen$233
  • Johnson & Johnson$202
  • Merck$190
  • Heartflow, Inc.$171
  • plus $794 from 11 others

What the payments were for

  • Travel & lodging$74025%
  • Food & beverage$2,23175%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,971 in reported general payments places this provider in the 85th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Medicare billing

Part B allowed, 2024
$3,550
Medicare patients
32
Services billed
48

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban138$150,747
EntrestoSacubitril/Valsartan25$30,448
XareltoRivaroxaban20$29,422
BrilintaTicagrelor18$15,793
FarxigaDapagliflozin Propanediol16$15,753
Carvedilol ErCarvedilol Phosphate19$6,909
Dofetilide12$4,166
Ranolazine ErRanolazine31$3,742
Midodrine Hcl28$2,526
Ezetimibe40$2,241
Rosuvastatin Calcium98$1,560
Metoprolol Succinate131$1,505
Isosorbide Mononitrate ErIsosorbide Mononitrate74$1,053
Carvedilol137$1,010
Atorvastatin Calcium144$1,003

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$36$150,747138 claims
AstraZenecaBrilinta, Farxiga$83$31,54634 claims
NovartisEntresto$152$30,44825 claims
Johnson & JohnsonXarelto$202$29,42220 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,332 family providers in Virginia.

Other family in Quantico

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →